Pfizer’s Maternal RSV Vaccine Quest May Hinge On FDA Advisors’ Views of Preterm Birth Data

 
• By Sarah Karlin-Smith
mom and infant
FDA’s advisors will vote 18 May on Pfizer’s maternal RSV vaccine program to protect infants • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers